Anti-complement drugs for the treatment of geographic atrophy and the release of silicone oil

被引:0
|
作者
Melo, Gustavo Barreto [1 ]
Emerson, Geoffrey Guy [2 ]
机构
[1] Univ Fed Sao Paulo, Dept Ophthalmol, Rua Botucatu 820, Sao Paulo, Brazil
[2] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN USA
关键词
Avacincaptad pegol; Pegcetacoplan; Geographic atrophy; Silicone oil; Syringe; SYRINGES;
D O I
10.1186/s40942-023-00523-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Intravitreal injections are a common procedure in ophthalmology, often using syringes coated with silicone to aid piston movement and needles coated with silicone oil to facilitate penetration of the sclera. Pegcetacoplan and avacincaptad pegol, recently approved for clinical use by the US Food and Drug Administration, have higher viscosity and seem more susceptible to entrap air bubbles compared to anti-VEGF drugs.It is plausible that both anti-complement drugs could be associated with a higher likelihood of introducing silicone oil in the vitreous because of higher viscosity, with potentially higher friction at the inner surface of syringe barrel, in the vicinity of silicone oil. In addition to this, undesirable agitation might be inadvertently promoted by some retina specialists to remove air bubbles from the drug solution.In conclusion, recent reports of silicone oil droplets in the vitreous of patients receiving pegcetacoplan injection might be related to both its viscosity and to agitation of the syringe to remove air bubbles. Since avacincaptad pegol also is viscous, though with different pH, syringe and filter needle, we might expect similar reports for this agent soon. We also recommend further studies be carried not only to clarify the current matter but also the potential association between the combination of agitation, silicone oil and inflammation or any immune response.
引用
收藏
页数:3
相关论文
共 8 条
  • [1] Anti-complement drugs for the treatment of geographic atrophy and the release of silicone oil
    Gustavo Barreto Melo
    Geoffrey Guy Emerson
    International Journal of Retina and Vitreous, 10
  • [2] Investigational drugs inhibiting complement for the treatment of geographic atrophy
    Desideri, Lorenzo Ferro
    Artemiev, Dmitri
    Bernardi, Enrico
    Paschon, Karin
    Zandi, Souska
    Zinkernagel, Martin
    Anguita, Rodrigo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (11) : 1009 - 1016
  • [3] Silicone oil-free syringes, siliconized syringes and needles: quantitative assessment of silicone oil release with drugs used for intravitreal injection
    Melo, Gustavo Barreto
    da Cruz, Natasha Ferreira Santos
    do Monte Agra, Lydianne Lumack
    Emerson, Geoffrey Guy
    Lima, Luiz H.
    Linkuviene, Vaida
    Maia, Mauricio
    Farah, Michel Eid
    Carpenter, John F.
    Rodrigues, Eduardo Buchele
    Probst, Christine
    ACTA OPHTHALMOLOGICA, 2021, 99 (08) : E1366 - E1374
  • [4] SOLUBILITY OF TRIAMCINOLONE ACETONIDE AND OTHER ANTI-INFLAMMATORY DRUGS IN SILICONE OIL Implications for Therapeutic Efficacy
    Carlos Pastor, Jose
    Jesus del Nozal, Maria
    Zamarron, Ester
    Garcia, Maite
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (09): : 1247 - 1250
  • [5] Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study
    Vangsted, Andreas
    Thinggaard, Benjamin S.
    Nissen, Anne H. K.
    Hajari, Javad N.
    Klefter, Oliver N.
    Nielsen, Marie Krogh
    Sorensen, Torben L.
    Grauslund, Jakob
    Subhi, Yousif
    ACTA OPHTHALMOLOGICA, 2023, 101 (08) : 857 - 868
  • [6] Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment
    Jakob Siedlecki
    Caroline Koch
    Benedikt Schworm
    Raffael Liegl
    Thomas Kreutzer
    Karsten U. Kortuem
    Ricarda Schumann
    Siegfried G. Priglinger
    Armin Wolf
    BMC Ophthalmology, 21
  • [7] Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment
    Siedlecki, Jakob
    Koch, Caroline
    Schworm, Benedikt
    Liegl, Raffael
    Kreutzer, Thomas
    Kortuem, Karsten U.
    Schumann, Ricarda
    Priglinger, Siegfried G.
    Wolf, Armin
    BMC OPHTHALMOLOGY, 2021, 21 (01)
  • [8] CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
    Schargus, Marc
    Werner, Benjamin P.
    Geerling, Gerd
    Winter, Gerhard
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (10): : 2088 - 2095